These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26206268)

  • 41. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials.
    Wacholder S; Chen BE; Wilcox A; Macones G; Gonzalez P; Befano B; Hildesheim A; Rodríguez AC; Solomon D; Herrero R; Schiffman M;
    BMJ; 2010 Mar; 340():c712. PubMed ID: 20197322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.
    Leroux-Roels G; Clément F; Vandepapelière P; Fourneau M; Heineman TC; Dubin G
    Hum Vaccin Immunother; 2013 Jun; 9(6):1254-62. PubMed ID: 23434737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.
    Garland SM; Ault KA; Gall SA; Paavonen J; Sings HL; Ciprero KL; Saah A; Marino D; Ryan D; Radley D; Zhou H; Haupt RM; Garner EIO;
    Obstet Gynecol; 2009 Dec; 114(6):1179-1188. PubMed ID: 19935017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association Between Incident Exposure to Benzodiazepines in Early Pregnancy and Risk of Spontaneous Abortion.
    Sheehy O; Zhao JP; Bérard A
    JAMA Psychiatry; 2019 Sep; 76(9):948-957. PubMed ID: 31090881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea.
    Kim CJ; Song R; Chen J; Tavares Da Silva F; Gopala KB; Kim JH; Bi D; Park JS
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):837-842. PubMed ID: 28266092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of the 2010-11, 2011-12, 2012-13, and 2013-14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS.
    Chambers CD; Johnson DL; Xu R; Luo YJ; Louik C; Mitchell AA; Schatz M; Jones KL;
    Vaccine; 2016 Aug; 34(37):4443-9. PubMed ID: 27449682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.
    Descamps D; Hardt K; Spiessens B; Izurieta P; Verstraeten T; Breuer T; Dubin G
    Hum Vaccin; 2009 May; 5(5):332-40. PubMed ID: 19221517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine.
    Dana A; Buchanan KM; Goss MA; Seminack MM; Shields KE; Korn S; Cunningham ML; Haupt RM
    Obstet Gynecol; 2009 Dec; 114(6):1170-1178. PubMed ID: 19935016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort.
    Dormuth CR; Winquist B; Fisher A; Wu F; Reynier P; Suissa S; Dahl M; Ma Z; Lu X; Zhang J; Raymond CB; Filion KB; Platt RW; Moriello C; Paterson JM;
    JAMA Netw Open; 2021 Apr; 4(4):e215329. PubMed ID: 33890993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth.
    Mølgaard-Nielsen D; Svanström H; Melbye M; Hviid A; Pasternak B
    JAMA; 2016 Jan; 315(1):58-67. PubMed ID: 26746458
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis.
    Wang A; Liu C; Wang Y; Yin A; Wu J; Zhang C; Luo M; Du L; Xiong Y; Zhao X; Huang Y
    Hum Vaccin Immunother; 2020 Mar; 16(3):581-589. PubMed ID: 31486334
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
    Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
    Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
    Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
    J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
    Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial.
    Aziz AB; Dudman S; Julin CH; Ahmmed F; Stene-Johansen K; Sandbu S; Øverbø J; Dembinski JL; Wisløff T; Rana S; Basunia AH; Haque W; Qadri F; Zaman K; Clemens JD
    Lancet Glob Health; 2024 Aug; 12(8):e1300-e1311. PubMed ID: 39030061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.